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Abstract
Background
HPV-16–positive HNSCC and HPV-16–negative HNSCC have different clinical factors, rep-
resenting distinct forms of cancers. The study aimed to identify patient-specific factors for
HPV-16-positive HNSCC based on baseline clinical data.
Method
Factors associated with HPV-16-positive HNSCC were identified using the data from 210
patients diagnosed with HNSCC at University College of London Hospital between January
1, 2003, and April 30, 2015, inclusive. A series of models were developed using logistic
regression methods, and the overall model fit was compared using Akaike Information Crite-
rion. Survival analysis was carried with Cox proportional hazards model for survival-time
outcomes. The survival time for individual patients was defined as the time from diagnosis of
HNSCC to the date of death from any cause. For patients who did not die, they were cen-
sored at the end of study on April 30, 2015.
Results
Of the 210 patients, 151 (72%) were found to have HPV-16-positive HNSCC. The logistic
regression model showed that the prevalence of developing HPV-16-positive HNSCC was
3.79 times higher in patients with Type 2 Diabetes Mellitus (T2DM) (odd ratio [OR], 3.79;
95% CI, 1.70–8.44) than in those without T2DM, and 8.84 times higher in patients with his-
tory of primary HNSCC (OR, 8.84; 95% CI, 2.30–33.88) than in those without a history of pri-
mary HNSCC. HPV-16–positive HNSCC was also observed more in tonsils (OR, 4.02; 95%
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CL, 1.56–10.36) and less in non-alcohol drinker’s oral cavity (OR, 0.14; 95% CI, 0.03–0.56).
Furthermore, individual patients were followed-up for 1 to 13 years (median of 1 year).
Patients with HPV-positive HNSCC had a median survival of 5 years (95% CI, 2.6–7.3
years). Among HPV-16–positive HNSCC cohort, T2DM was a risk for poorer prognosis
(hazard ratio, 2.57; 95% Cl, 1.09–6.07), and had lower median survival of 3 years (95% CI,
1.8–4.1 years), as compared to 6 years (95% CI, 2.8–9.1 years) in non-T2DM.
Conclusions
Patient-specific factors for HPV-positive HNSCC are T2DM, history of primary HNSCC and
tonsillar site. T2DM is associated with poorer prognosis. These findings suggest that it might
be beneficial if routine HPV-16 screening is carried out in T2DM patients which can provide
better therapeutic and management strategies.
Introduction
Over the past 3 decades, an increase in the incidence of human papillomavirus (HPV)-pos-
itive head and neck cancer (HNSCC), particularly oropharyngeal cancer, has been
observed in the United Kingdom, most notably among men under the age of 60 [1]. Previ-
ous reports suggest that HPV-positive HNSCC and HPV-negative HNSCC are heteroge-
neous, representing distinct subtypes of HNSCC, each with different risk and prognostic
factors [2–6].
Few studies developed risk predictive models of tumor HPV-16–status using tumor bio-
markers [2] or histopathological features [4]. Features of a patient with HPV-16–positive
HNSCC is younger onset, male predominance, limited or no prior smoking or alcohol use,
white race and the presence of pathological factors such as oropharynx primary tumor, p16
protein overexpression, poor tumor differentiation, basaloid features, and non-keratinizing
cell types on histopathologic analysis. However, currently there are no accepted predictive
models to identify patient specific factors of HPV-16–positive HNSCC based on baseline
demographic and clinical data. This may lead physicians to make ad hoc decisions about
which patients to receive routine HPV-16 screening, and risk delay in testing those who are
at risk of HPV-16–positive HNSCC development. Thus, establishing a link between patient
clinical and medical history data such as co-morbidities and tumor HPV status can provide
valuable insights as to which patients should undergo routine screening. Therefore, we
developed a methodology to identify patient-specific factors for HPV-16–positive HNSCC
based on baseline clinical and medical history data. We also followed-up individual patients
for 1 to 13 years (median of 1 year), to identify which patient factors are associated with
poorer prognosis.
Materials and methods
Ethical considerations
The study protocol was approved by the Institutional Review Board of the UCLH. The ethic
number for the study is 04/Q0505/59 by National Research and Ethics Committee (NRES)
London-Harrow through University College of London Hospitals NHS Foundation Trust.
Patients’ records were fully anonymized prior to access.
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Study population
The study cohort was derived from the head and neck cancer department medical records at
University College of London Hospital (UCLH). Patients diagnosed with HNSCC between
January 1, 2003, and April 30, 2015, at UCLH were included, inclusive. Patients were eligible
for inclusion if they were older than 18 years and were newly diagnosed with a histological
confirmed squamous cell carcinoma of the oral cavity, oropharynx, tonsils, hypopharynx, lar-
ynx, nasopharynx, or multiple HNSCC tumor sites. Multiple HNSCC tumor sites was defined
as the presence of two or more tumors synchronously in head and neck region. Anatomic site
of the tumor was determined by a physical examination that was performed by the treating
head and neck surgeon. SPSS file consisting of all patients’ parameters used in model predic-
tion for the study is provided in S1 File.
HPV-16 in situ hybridization
The outcome of interest was tumor HPV-16 status. Patients were classified as having a diagno-
sis of either HPV-16-positive or HPV-16-negative HNSCC based upon HPV-16 DNA detec-
tion in formalin-fixed and paraffin-embedded (FFPE) tumors using the in situ hybridization
approach for biotinylated probes [7]. Tissue consists of triplicate tumor cores from corre-
sponding FFPE blocks from all patients were constructed. The positive control was p16 IHC
and the negative control was inflamed tonsil tissue. Specific staining of tumor cell nuclei for
HPV-16 defined a positive tumor.
Univariate analysis of variables
Patient independent variables consisted of demographic variables, including age and sex; co-
morbid conditions, including type 2 diabetes mellitus (T2DM), hypertension, vascular dis-
eases, previous primary HNSCC, history of current or former smoking, or alcohol use; treat-
ments history, including use of anti-hypertensives, hypoglycemic agents, or anti-infective for
systemic use; and HNSCC tumor anatomic sites. A patient’s co-morbid conditions and treat-
ment history were categorized as present or absent at the time of HNSCC diagnosis. The ana-
tomic sites of head and neck included in the analysis were oropharynx, tonsils, oral cavity,
larynx, hypopharynx, paranasal sinus, and nasopharynx. In this study, a large number of our
patients (36%) were diagnosed with HPV-positive tonsillar carcinoma; therefore, tonsils which
is a part of the oropharynx anatomic site were analyzed separately. Oropharynx included
tumor in soft palate and uvula.
All selected variables were tested for multi co-linearity to avoid any strong correlation
between the variables. The presence of co-linearity was examined by the evaluation of variance
inflation factors and magnitude of standard errors. Variables with more than 30% missing val-
ues were not included in the analysis. All other missing data were imputed using the multiple
imputation technique using SPSS (version 21; SPSS, Inc., Chicago, IL).
Multivariate analysis and model development
The first aim of this study was to identify patient- specific factors associated with HPV-16–pos-
itive HNSCC based on baseline demographic and clinical data. Therefore, we developed a
sequential series of logistic regression models using HPV-16–positive HNSCC as the depen-
dent variable (Fig 1). We used a combination of clinical medical guidance and forward selec-
tion method to determine variable selection [8, 9]. Using univariate analysis, variables not
associated with HPV-16–positive HNSCC (P>0.10) were excluded from further analyses.
Variables were then entered in each model in accordance with the chronology in which patient
Prognostic and risk factors of HPV-16 positivity in HNSCC
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Fig 1. The flow chart of study methodology. Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV,
human papillomavirus, T2DM; type 2 diabetes mellitus, UCLH, University College of London Hospital. �A significant
interaction (P< .05) was identified between the oral cavity tumor site and alcohol use; therefore, to remove their
simultaneous influence both were added to the final model.
https://doi.org/10.1371/journal.pone.0217000.g001
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demographic and clinical data were available at the time of HNSCC diagnosis. Model with
more variables or with greater complexity was successively compared with the simple ones.
Using this approach, 4 Models were generated from the data provided.
Model 1, was developed by adding patient demographics (age and male sex). Model 2, was
developed by adding patient co-morbidities (T2DM, previous HNSCC, and alcohol use) and
compared with model 1. Model 3, was developed by adding patient HNSCC tumor anatomic
sites (tonsils and oral cavity) and compared with model 2. We then tested for interaction
effects between predictors or variables retained in model 3. A significant interaction (P< 0.05)
was identified between the oral cavity tumor site and alcohol use; therefore, both variables
were added to the final model (Model 4).
Model performance evaluation
Improvement in model performance through the addition of new variables in multivariate
logistic regression models was tested using measures of discrimination and goodness of fit.
The discriminatory power of each model was assessed using concordance statistics (C statis-
tics). Discrimination refers to the ability of a model to clearly distinguish between 2 groups
of outcomes (discriminate between the HPV-16–positive HNSCC and HPV-16–negative
HNSCC patient groups) and can range from 0.5 (no discrimination) to 1.0 (perfect discrim-
ination) [10, 11]. The overall model fit for sequential models was compared using Akaike
Information Criterion (AIC), which considers both the statistical goodness of fit and the
number of variables required to achieve this particular degree of fit by imposing a penalty
for increasing the number of variables. The optimal fitted model was selected by the mini-
mum value of AIC [11]. We used AIC over the BIC (Bayesian Information Criterion)
because selection with BIC may lead to “under-fitting,” since BIC penalizes larger models
by excluding many predictors [11]. The accuracy of the final model was evaluated using
positive predictive value (percentage of truly positive among those predicted HPV-positive
HNSCC), and negative predictive value (percentage of truly negative among those predicted
HPV-positive HNSCC). Sensitivity (percentage predicted positive among all truly positive)
and specificity (percentage predicted negative among all truly negative) were also
calculated.
Survival analysis
The second aim of this study was to compare the median survival time between patients with
HPV-positive and HPV-negative tumors during the follow-up period of 1 to 13 years (median
of 1 year). We also compared the median survival time between T2DM and non-T2DM sub-
groups within the HPV-positive HNSCC cohort. The survival time for individual patients was
defined as the time from diagnosis of HNSCC to the date of death from any cause. For patients
who did not die, they were censored at the end of study on April 30, 2015. Survival probability
was computed with a Cox proportional hazards model and the resultant cumulative survival
probability curve was plotted. Cox proportional hazards model was adjusted for age, male sex,
alcohol use, smoking, and American Society of Anesthesiologist (ASA) co-morbidity score
[12].
All analyses were performed using SPSS 21.0. Categorical variables are presented herein as
percentages, and the continuous variable (age) are presented as means (SDs). The age variable
was assessed for normality using the Kolmogorov-Smirnov test. Comparisons of categorical
variables were performed using the chi-square (χ2) test or Fisher exact test. A finding of
P< 0.05 was considered indicative of a statistically significant difference for all tests.
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Results
Following a review of the medical records, we determined that 210 patients were diagnosed
with HNSCC at UCLH, 151 of which were HPV-16–positive HNSCC (72%). Consistent with
recent epidemiological studies [1, 6, 13], almost two-third of the patients in this study had
HPV-related tumors in oropharyngeal sites (100 cases out of 151, 66%). Of those 100 patients
with HPV-16–related oropharyngeal cancer, 54 patients had carcinoma of the tonsillar regions
(Table 1).
Univariate analysis of HNSCC variables
The patient demographic and clinical characteristics captured in the database are listed in
Table 1. The mean age was similar between the HPV-16–positive and HPV-16–negative
patient groups (61 years), with more males in the HPV-16–positive compared to HPV-16–neg-
ative patient groups (74% vs 63%, P = 0.100). Compared to HPV-16–negative patient groups,
those with HPV-16–positive HNSCC had significantly higher number of co-morbidities such
as T2DM (45% vs 27%, P = 0.017), history of primary HNSCC (18% vs 7%, P = 0.042), or alco-
hol use history (77% vs 49%, P<0.001); and had significantly higher and lower rates of
HNSCC in tonsils (36% vs 12%, P<0.001) and oral cavity (19% vs 37%, P<0.006), respectively.
Multivariate analysis of HNSCC data using statistical model development
The odd ratios for the variables and statistics for discrimination and goodness of fit for succes-
sive models are shown in Table 2. Model 1, including age and sex only, performed poorly (C
statistic, 0.563; 95% confidence interval [CI], 0.476–0.650, and AIC 250.57; P< 0.001). How-
ever, the C statistic and AIC improved with the inclusion of patient co-morbidities such as
T2DM, history of primary HNSCC, and alcohol use in model 2 (0.760; 95% CI, 0.689–0.832,
and 222.17; P< 0.001), and HNSCC anatomic sites such as tonsils and oral cavity in model 3
(0.800; 95% CI, 0.732–0.868, and 211.97; P< 0.001). After the addition of interaction terms
between alcohol use and oral cavity in model 4, test results were significantly associated with
HPV-16–positive HNSCC for presence of T2DM, history of primary HNSCC, and HNSCC
sites in tonsils and non-alcohol drinker’s oral cavity (0.825; 95% CI, 0.761–0.889, and 203.51;
P< 0.001). The final model showed a good predictive ability for tumor HPV-16–status
(n = 210, sensitivity (%) of 81, specificity (%) of 76, positive predictive value (%) of 94, and neg-
ative predictive value (%) of 42).
Survival analysis
Individual patients were followed-up for 1 to 13 years (median of 1 year), during which time
47 deaths occurred. Patients with HPV-positive HNSCC had a median survival of 5 years (95%
CI, 2.6–7.3 years). HPV-positive HNSCC cohort with T2DM and a history of previous
HNSCC, or with diagnosis of tonsillar or oral cavity were further stratified. A multivariate Cox
proportional hazards regression analysis, adjusted for sex, age, alcohol use, smoking, and ASA
co-morbidity score, revealed that among above-mentioned HPV-positive HNSCC specific fac-
tors, T2DM were a risk for poorer prognosis (hazard ratio, 2.57; 95% Cl, 1.09–6.07), and had
lower median survival of 3 years (95% CI, 1.8–4.1 years), as compared to 6 years (95% CI, 2.8–
9.1 years) in non-T2DM. (Table 3 and Fig 2).
Discussion
In this study, we developed a series of risk prediction models in a cohort of HNSCC to identify
patient specific factors associated with tumor HPV-16 status. A comprehensive clinical
Prognostic and risk factors of HPV-16 positivity in HNSCC
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predictive model would serve to help clinicians decide which patient-factor is associated with
higher prevalence of HPV-16–positive HNSCC. As there is a different factors associated with
tumor HPV-16–status, we also followed-up individual patients for 1 to 13 years (median of 1
year), and found that there is also heterogeneity in the prognostic factors associated with
tumor HPV-16-status.
Several prior studies have developed prediction models from several likely patient-related
factors in patients with HNSCC [2, 4].Byrd et al [4] showed that a multivariable model includ-
ing socio-demographic and histopathological factors was moderately successful at predicting
HPV-16-status among HNSCC. The only variables significantly related to HPV-16-status were
male sex (P = .01) and oropharyngeal subsite (P = 0.02). Similarly, D’Souza et al [2] found that
models that used a combination of demographic characteristics such as age, tobacco use, male
sex, and race had only moderate predictive value for tumor HPV-16–status among all patients
with HNSCC (n = 225, sensitivity (%) of 76 and specificity (%) of 60) or when limited to oro-
pharynx cancer patients (n = 119, sensitivity (%) of 84 and specificity (%) of 31). Addition of
behavioral factors such as lifetime number of sexual partners, family income, education; or
biomarkers of HPV-16 exposure such as L1, E6/7 antibodies or DNA in oral exfoliated cells to
the multivariate model did not improve prediction. Nevertheless, in our study, variables were
added in each model in accordance with the chronology in which patient demographic and
Table 1. Baseline characteristics of study cohort.
No. (%) of Patients
Characteristics HPV-16–positive HNSCC
(n = 151)
HPV-16–negative HNSCC
(n = 59)
P value
Demographic
Age, mean (SD), y 61 (12) 61 (11) 0.742
Male sex 112 (74) 37 (63) 0.100
Co-morbidities
Hypertension 17 (11) 5 (8) 0.554
Cardiovascular diseases 29 (19) 11 (19) 0.926
T2DM 68 (45) 16 (27) 0.017
Previous malignancies 62 (41) 30 (51) 0.218
Previous primary HNSCC 27 (18) 4 (7) 0.042
History of current or former smoker 109 (72) 40 (68) 0.529
Alcohol use 117 (77) 29 (49) <0.001
Smokeless tobacco 6 (4) 4 (7) 0.391
Treatment history
Antihypertensive 16 (11) 2 (3) 0.107
Hypoglycemic agents 9 (6) 3 (5) 0.806
Antidepressants 6 (4) 1 (2) 0.408
Anti-infective for systemic use 6 (4) 6 (10) 0.101
HNSCC anatomic sites
Oral cavity 29 (19) 22 (37) 0.006
Oropharynx 37 (24) 9 (15) 0.145
Tonsils 54 (36) 7 (12) 0.001
Multiple HNSCC sites 24 (16) 6 (10) 0.287
Other HNSCC sites� 7 (5) 15 (25) <0.001
Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus, T2DM; type 2 diabetes mellitus.
�Other HNSCC tumor sites included tumors in larynx (n = 10), or hypopharynx (n = 5), or nasopharynx (n = 4), or paranasal sinus (n = 3).
https://doi.org/10.1371/journal.pone.0217000.t001
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clinical data were available at the time of HNSCC diagnosis. The final model showed a good
predictive ability for tumor HPV-16 status (n = 210, the sensitivity of 81% and specificity of
76%). The advantage of our method is in its simplicity and potentially using more patient-cen-
tered approach enabling clinicians to identify high-risk groups of patients for HPV-16 status
who may benefit from preventive measures such as routine screening for oral HPV-16 infec-
tion, thereby minimizing their risk of HPV-16related HNSCC [14].
In this study, we found that patients who had a history of primary HNSCC were signifi-
cantly at higher risk of recurrent second primary HPV-16–positive HNSCC. Our finding cor-
relates with previous studies that have reported a trend between previous HNSCC and second
primary HNSCC in an era of oncogenic HPV [15, 16]. Diaz et al. [16] performed a study in
Surveillance, Epidemiology, and End Results (SEER) database (1973–2008) for 104,639
patients with an index HNSCC, and found that 4616 (4.4%) had second primary HPV-positive
oral cavity/pharyngeal cancers. The author concluded that there is a shift in HNSCC etiology
to a tumor primarily caused by oncogenic HPV over tobacco associated HNSCC. Now, the
question that arises is whether persistent HPV infection in the head and neck region is a risk
factor for pharyngeal cancer which hasn’t been rigorously explained [17]. However, certain
groups of patients with index HNSCC may likely benefit from routine HPV-16 screening mea-
sures [14, 18] making our model potentially useful for further research as we identified high-
risk patients for HPV-16–positive HNSCC development.
A noteworthy finding in our study was that patients with T2DM were significantly associ-
ated with higher prevalence of HPV-16–positive HNSCC and were associated with poorer
prognosis in HPV-16-positive HNSCC subgroups. Numerous epidemiological studies have
reported a higher risk of oral precancerous lesions [19] and oropharyngeal cancer in patients
Table 2. Odd ratios and goodness of fit for sequential models to predict a HPV-16–positive HNSCC.
Models
Variables 1 2 3 4
Demographic Demographic +
Co-morbid
conditions
Demographic +
Co-morbid conditions + HNCSS
anatomic sites
Demographic +
Co-morbid conditions HNCSS anatomic
locations +
Effect modifications��
Age, 1-y increase 0.99 (0.96–1.02) 1.00 (0.97–1.03) 1.00 (0.97–1.03) 1.01 (0.97–1.04)
Male sex 1.72 (0.90–3.29) 1.54 (0.75–3.14) 1.50 (0.71–3.14) 1.46 (0.68–3.15)
T2DM 3.36 (1.61–6.99) 3.67 (1.70–7.91) 3.79(1.70–8.44)
Previous primary HNSCC 6.67 (2.00–22.23) 7.86 (2.30–26.82) 8.84 (2.30–33.88)
Alcohol 4.32 (2.14–8.73) 4.15 (1.97–8.73) 1.94 (0.79–4.74)
Tonsils 4.18(1.58–11.05) 4.02(1.56–10.36)
Oral cavity 0.68 (0.31–1.52) 0.14 (0.03–0.56)
Alcohol x Oral cavity 15.85 (2.63–95.20)
C statistic� 0.563 (0.476–
0.650)
0.760 (0.689–0.832) 0.800 (0.732–0.868) 0.825 (0.761–0.889)
Akaike� Information
Criterion
250.57 222.17 211.97 203.51
P value < .001 < .001 < .001 < .001
Abbreviations: HNSCC, head and neck squamous cell carcinoma, T2DM; type 2 diabetes mellitus.
Data are presented as odd ratios (95% confidence interval) unless otherwise specified.
� Higher values for C statistic and lower values for Akaike Information Criterion indicate better models.
�� A significant interaction (P< .05) was identified between the oral cavity tumor site and alcohol use; therefore, to remove their simultaneous influence both were
added to the final model (model 4). The resultant OR for the oral cavity tumor site is specific for non-alcohol drinkers.
https://doi.org/10.1371/journal.pone.0217000.t002
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with DM [20, 21], and some also revealed that DM are correlated with poorer prognosis[20,
22]; however, these studies were unable to control for tumor HPV status. One possible expla-
nation that relates T2DM to HPV-associated HNSCC, is that DM (particularly if glycemic con-
trol is poor, HbA1c >9%) is associated with an increased prevalence of periodontitis [23], and,
chronic periodontitis is associated with HPV-positive oropharyngeal cancer [24]. Periodontitis
is a chronic oral infection caused by inflammatory reactions to gram-negative anaerobic bacte-
ria in the dental plaque [25]. It results in continuous release of inflammatory cytokines, includ-
ing interleukins (IL)-1, IL-6, and tumor necrosis factor-α, that modulate proliferation of HPV
and expression of its oncogene E6/E7 in epithelial cells [26]. Subsequently, the expression of
the E6/E7 oncogenes can lead to early compromise of the innate immune system (loss of anti-
gen-presenting cells) promoting HPV persistence and increased risk of cancer [27]. The peri-
odontal pocket may also act as a reservoir for latent HPV [28].Thus, another reasonable
explanation that links T2DM to the development of HNSCC may be their long-term exposure
to HPV. Most HPV infections are cleared rapidly by an intact immune system and do not lead
to cancer. But the lower immune response of DM [29] facilitates persistence of HPV infection
that is considered as the main risk factor for carcinogenesis [30]. Moreover, T2DM is being
redefined as an auto-immune disease [31–33], which may directly promote tumors [34–36]: B
cell effects on glucose metabolism are linked to the production of pathogenic IgG antibodies
[31]. Recently, an article has shown that long-term exposure to hyperinsulinemia in T2DM
can lead immune T-cell to develop reduced sensitivity to its insulin receptors and result in
impaired insulin signaling; therefore, these functional defect of insulin receptors on T cell may
impose certain restrictions on antigen-specific T-cell immunity in T2DM [37]. There is
another report that the presence of glutamic acid decarboxylase antibodies in latent autoim-
mune diabetes sub-groups in adults [33], has been associated with the development of multiple
cancers [38]. In this study, we also found that after adjusting for the age, gender, alcohol use,
Table 3. Summary of survival outcome of patients with HPV-16 positive HNSCC.
Median survival rate in years (95%
CI)
HR (95% CI�) P-value�
A. Survival
HPV-16 negative HNSCC 5 1
HPV-16 positive HNSCC 5 (2.6–7.3) 1.08 (0.46–
2.51)
0.851
B. Survival in Subgroups with HPV-16 positive
HNSCC
Non-T2DM 6 (2.8–9.1) 1
T2DM 3 (1.8–4.1) 2.57 (1.09–
6.07)
0.031
Non-previous primary HNSCC 4 (1.3–6.6) 1
Previous primary HNSCC 6 (2.3–9.6) 0.68 (0.19–
2.33)
0.542
Non-tonsil 4 (2.7–5.2) 1
Tonsil 13 0.39 (0.13–
1.20)
0.104
Non-oral cavity 4 (2.1–5.8) 1
Oral cavity 7 0.80 (0.26–
2.44)
0.70
�P-value are adjusted for age, male sex, alcohol, smoking, and ASA comorbidity score
https://doi.org/10.1371/journal.pone.0217000.t003
Prognostic and risk factors of HPV-16 positivity in HNSCC
PLOS ONE | https://doi.org/10.1371/journal.pone.0217000 May 16, 2019 9 / 14
and ASA co-morbidity score, T2DM had lower survival rate as compared to non-T2DM
within the HPV-16 positive HNSCC groups. A previous preclinical study [39] revealed that
prolonged glucose incubation or hyperglycemia could enhance HNSCC malignancy in time-
course manner and be the reason behind increased resistance of DM to cisplatin chemother-
apy agent. The authors emphasized on the requirement of tight glycemic control for clinical
practice to achieve better prognostic outcomes for DM patients with HNSCC.
In our patients, HPV-16–associated HNSCC predominantly affected the tonsillar region,
compared to the small percentage of tumors at the oral cavity. Our results are consistent with
the previous findings that showed a higher prevalence of oncogenic HPV-16-DNA in palatine
tonsils (50%) [40], compared to other HNSCC-tumor subtypes, such as oral cavity (12–18%),
hypopharynx (13–25%), and larynx (3–7%) [41]. The reasons behind tonsils being more sus-
ceptible than other head and neck sites to HPV-16–DNA is unclear. It is known that tonsillar
crypt epithelium capture and process antigens, which in turn facilitate viral access to the basal
cells. It is possible that HPV-16–virus persists in the crypt epithelium and even in tonsillar
lymphoid tissue, which makes the tonsillar tissue to be as HPV-16–reservoir in the head and
neck regions [40]. It is also postulated that persistence of HPV-16–DNA in tonsillar lymphatic
tissue could be of importance in the immune response to HPV-16 infection [40]; this cellular
immune response is a key factor in the fight against HPV infections and related cancer. It can
be the reason behind a better prognosis that we had seen in patients with HPV-positive tonsil-
lar carcinoma as compared to non-tonsillar carcinoma.
Fig 2. Cumulative survival probability of patients with T2DM or non-T2DM human papillomavirus-16 positive HNSCC. �The T2DM status for 8 patients
with HPV-positive HNSCC was unknown. Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus, T2DM; type 2
diabetes mellitus.
https://doi.org/10.1371/journal.pone.0217000.g002
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Similar to any observational study, this investigation has a number of limitations. Although,
through development of a series multivariate logistic regression models, the effect of observed
confounders were adjusted, there might be a number of unobservable factors that could only
be controlled with a randomized controlled trial. In addition, the limited sample size of this
study could have resulted in some bias in the results produced. We also cannot exclude the
possibility of associations between patient sexual behavior and HPV-16–positive HNSCC
since we did not have access to this factor. Finally, this study was performed in one hospital,
which may also limit the generalization of the results. Nonetheless, the data presented in this
study are the first, to our knowledge, to suggest that T2DM is a prognostic factor for HPV-16
positive HNSCC, thus, these findings will need to be confirmed in a larger database, and the
impact of preventive measures such as routine HPV-screening, testing for HPV, and even the
prophylactic effects of HPV-vaccination on these high-risk groups be evaluated. Our findings
could lead to further research about the impact of T2DM for promoting viral carcinogenesis
and in deciphering the molecular mechanisms behind T2DM lower responsiveness to chemo-
therapy agents.
Conclusions
In conclusion, our data show that history of primary HNSCC and occurrence of HNSCC in
the tonsillar regions are patient-specific factors for HPV-positive HNSCC. We also were able
to identify T2DM as a prognostic factor for HPV-positive HNSCC suggesting potential pre-
ventive strategy through HPV-16 screening of T2DM patients.
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